Co-Diagnostics, Inc. Announces Second Quarter 2025 Earnings Release Date and Webcast

Rhea-AI Summary

Co-Diagnostics (NASDAQ:CODX), a molecular diagnostics company, has scheduled its second quarter 2025 earnings release for Thursday, August 14, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET the same day.

Key executives participating in the call include CEO Dwight Egan, CFO Brian Brown, and Head of IR Andrew Benson. Investors can access the webcast through the company's IR website and join the conference call via toll-free (888-880-3330) or toll (646-357-8766) numbers. A recording will be available on the company's website for those unable to attend.

News Market Reaction

+0.78%

1 alert

+0.78% News Effect

-4.1% Trough Tracked

+$67K Valuation Impact

$9M Market Cap

0.4x Rel. Volume

On the day this news was published, CODX gained 0.78%, reflecting a mild positive market reaction. Argus tracked a trough of -4.1% from its starting point during tracking. This price movement added approximately $67K to the company's valuation, bringing the market cap to $9M at that time.

Data tracked by StockTitan Argus on the day of publication.

SALT LAKE CITY, July 31, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its second quarter 2025 financial results on Thursday, August 14, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts.  Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations.

The conference call and webcast will be available via:

Webcast: ir.co-dx.com on the Events & Webcasts page, or accessible directly here

Conference Call: 888-880-3330 (Toll Free) or (646) 357-8766 (Toll)

If you are unable to participate during the live webcast, the call will be recorded and later made available on the Company's website.

About Co-Diagnostics, Inc.
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to identify genetic markers for use in applications other than infectious disease.

View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-announces-second-quarter-2025-earnings-release-date-and-webcast-302518325.html

SOURCE Co-Diagnostics

FAQ

When will Co-Diagnostics (CODX) release Q2 2025 earnings?

Co-Diagnostics will release its Q2 2025 earnings on Thursday, August 14, 2025 after the market close.

How can investors access Co-Diagnostics Q2 2025 earnings call?

Investors can access the earnings call via webcast at ir.co-dx.com or by phone at 888-880-3330 (toll-free) or 646-357-8766 (toll) on August 14, 2025 at 4:30 p.m. ET.

Who will participate in Co-Diagnostics Q2 2025 earnings call?

The earnings call will feature CEO Dwight Egan, CFO Brian Brown, and Head of IR Andrew Benson.

Will Co-Diagnostics Q2 2025 earnings call be recorded?

Yes, the earnings call will be recorded and made available later on the company's website for those unable to attend the live webcast.